Skip to main content

Market access for medical technologies in Finland

A brief overview of key market access pathways and challenges for medical devices, in-vitro diagnostic tests in Finland


Key topics

There are three key themes describing market access for medical technologies in Finland: 

  • Reimbursement: payment mechanism via the DRG system and regional price lists
  • Funding: recommendations by the national Council for Choices in Health Care
  • Health technology assessment: obtaining recommendations from the national and local HTA bodies


There is no national reimbursement or funding model for healthcare services in Finland. Wellbeing counties in Finland are funded in different ways. Local price lists (fee-for-service), activity-based funding on the basis of diagnosis-related groups (DRGs), and global budget adjusted for DRG activity are the three most common ways of financing health care services.

Finland shares the DRG system (NordDRG) with several other countries, including Sweden and Norway. However, all inter-regional care is reimbursed on a case-by-case basis via the DRG system. Therefore, the role of DRG is higher for procedures, which are concentrated only in several hospitals across the country, and which provide care for patients from other Finnish wellbeing areas. 

DRGs are determined by the combination of a procedure code (THL) and a diagnosis code (ICD-10). THL nomenclature is maintained by the Finnish Institute for Health and Welfare and released a few times a year. The Finnish version of the NordDRG system is approved annually.



Finland has no nationally defined list of health benefits that are guaranteed to the Finnish population. Decisions on which treatment methods to use and which new technologies to introduce are made by the hospitals.

In order to promote equal access, cost-effective, and efficient use of medical technologies in the country, the Council for Choices in Health Care in Finland (COHERE) evaluates technologies and provides recommendations for the adoption of novel technologies to payers (wellbeing areas) and healthcare providers. 


Health technology assessment

HTA is performed on the national level (as part of the COHERE recommendations or stand-alone assessments by the Finnish Coordinating Center for Health Technology Assessment) or on the local level (which can inform hospital decision-making).


Specifics for IVD tests

There is no specific reimbursement framework for in-vitro diagnostic tests in public laboratories. IVD tests are funded using a global budget principle as part of the laboratory funding.

The Social Insurance Institution of Finland (Kela) reimburses IVD tests performed in private laboratories ordered by private physicians.

MTRC has experience with more than 77 projects in Finland

News and insights

HTAs in Finland in June 2024

In June 2024, the Finnish Coordinating Center for Health Technology Assessment announced that two rapid hospital assessments in the extracorporeal treatments and endoscopy fields and one Digi-HTA were accomplished.

Laboratory test nomenclature updated in Finland

On April 18, 2024, the updated version of the Finnish Laboratory Tests Nomenclature was published by the Finnish Institute for Health and Welfare (THL) to come into force on May 1, 2024. A total of four new codes were introduced in the in-vitro diagnostic field.

2024 Finnish NordDRG system came into force

On January 1, 2024, the annual update of the Finnish NordDRG system came into force. A total of 63 new DRGs were introduced concerning men’s health, nephrology and urology, neurology, neuromodulation, obstetrics and gynecology, surgical procedures, and other fields.

Get in touch